Immunogenicity of recombinant vaccinia viruses that display the HIV type 1 envelope glycoprotein on the surface of infectious virions

AIDS Research and Human Retroviruses

Volumn 13, Issue 17, 1997, Pages 1497-1500

  Katz, Ehud ^a   Moss, Bernard ^b  

^a HEBREW UNIVERSITY   (Israel)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; VACCINIA VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANTIGEN PRESENTATION; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRION;

EID: 0030771564     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.1497     Document Type: Article

References (14)

1. Cooney EL, McElrath MJ, Corey L, Hu SL, Collier AC, Arditti D, Hoffman M, Coombs RW, Smith GE, and Greenberg PD: Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160-protein. Proc Natl Acad Sci USA 1993;90:1882-1886.
2. Graham BS, Matthews TJ, Belshe RB, Clements ML, Dolin R, Wright PF, Gorse GJ, Schwartz DH, Keefer MC, Bolognesi DP, Corey L, Stablein DM, Esterlitz JR, Hu SL, Smith GE, Fast PE, and Koff WC: Augmentation of human immunodeficiency virus type-1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J Infect Dis 1993;167:533-537.
3. Pialoux G, Excler JL, Riviere Y, Gonzalez-Canali G, Feuillie V, Coulaud P, Gluckman JC, Matthews TJ, Meignier B, Kieny MP, Gonnet P, Diaz I, Méric C, Paoletti E, Tartaglia J, Salomon H, Plotkin S, the Agis Group, and l'Agence Nationale de Recherche sur le SIDA: A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res Human Retroviruses 1995;11:373-381.
4. Earl PL, Moss B, and Doms RW: Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J Virol 1991;65:2047-2055.
5. Moss B. Poxviridae: The viruses and their replication. In: Fields Virology (Fields BN, Knipe DM, and Howley PM, Eds.), 3rd ed. Lippincott-Raven, Philadelphia, 1996, pp. 2637-2671.
6. Katz E, Wolffe EJ, and Moss B: The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccina virions. J Virol 1997;71:3178-3187.
7. Hirsch VM, Fuerst TR, Sutter G, Carroll MW, Yang LC, Goldstein S, Piatak M Jr, Elkins WR, Alvord WG, Montefiori DC, Moss B, and Lifson JD: Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 1996;70:3741-3752.
8. El-Ad B, Roth Y, Winder A, Tochner Z, Lublin-Tennenbaum T, Katz E, and Schwartz T: The persistence of neutralizing antibodies after revaccination against smallpox. J Infect Dis 1990;161: 446-448.
9. Chakrabarti S, Brechling K, and Moss B: Vaccinia virus expression vector: Coexpression of β-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 1985;5:3403-3409.
10. Earl PL, Hügin AW, and Moss B: Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J Virol 1990;64:2448-2451.
11. Blasco R and Moss B: Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J Virol 1992;66:4170-4179.
12. Blasco R and Moss B: Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000 Dalton outer envelope protein. J Virol 1991;65:5910-5920.
13. McIntosh AAG and Smith GL: Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus. J Virol 1996;70:272-281.
14. Wolffe EJ, Katz E, Weisberg A, and Moss B: The A34R glycoprotein gene is required for induction of specialized actin-containing microvilli and efficient cell-to-cell transmission of vaccinia virus. J Virol 1997;71:3904-3915.